Pfizer and GlaxoSmithKline Form Pact in Combination Cancer Trial - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer and GlaxoSmithKline Form Pact in Combination Cancer Trial
Phase I/II study to evaluate treatment of patients with melanoma using Pfizers palbociclib and GSKs trametinib.


Pfizer announced that it has entered into an agreement with GlaxoSmithKline (GSK) to assess safety and efficacy of Pfizer’s palbociclib plus GSK’s trametinib combination therapy in patients with advanced/metastatic melanoma.

The Phase I/II trial is a dose-escalation, open-label study, designed to determine the recommended combination regimen (RCR) for palbociclib plus trametinib in patients with melanoma. The study will also evaluate the effect of the combination therapy on tumor biomarkers, safety and anti-cancer activity in patients with BRAFV600 wild type melanoma, including those with NRAS mutations.

Both Pfizer and GSK will collaborate on the study, which will be conducted by GSK. Financial terms of the agreement were not disclosed.

Palbociclib is an investigational oral selective inhibitor of cyclin dependent kinases (CDK) 4 and 6 developed by Pfizer. The agent received breakthrough designation by the FDA in April 2013 for the potential treatment of patients with breast cancers. Palbociclib is not approved for any indication in any markets.

Trametinib, a reversible inhibitor of MEK1 and MEK2 developed by GSK, is approved by the FDA under the trade name Mekinist for the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation as detected by an FDA-approved test. Mekinist is not indicated for the treatment of patients who have received a prior BRAF inhibitor therapy.

Source: Pfizer

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
21%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
8%
Regulatory compliance
42%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here